Document is current
Any future updates will be listed below
-
Authors
Loehrer, Philipp A. https://orcid.org/0000-0002-5279-2156
Bopp, Miriam H. A. https://orcid.org/0000-0003-1574-7572
Dafsari, Haidar S. https://orcid.org/0000-0001-8849-4233
Seltenreich, Sieglinde
Knake, Susanne
Nimsky, Christopher https://orcid.org/0000-0002-8216-9410
Timmermann, Lars
Pedrosa, David J. https://orcid.org/0000-0002-5403-1959
Belke, Marcus
-
Funding
Funding for this research was provided by:
Philipps-Universität Marburg
Stiftung zur Förderung junger Neurowissenschaftler
EU Joint Programme – Neurodegenerative Disease Research
Prof. Klaus Thiemann Foundation Felgenhauer Foundation KoelnFortune program
- License Information
-
More Information
Article History
Received: 31 August 2023
Accepted: 25 April 2024
First Online: 18 May 2024
Competing interests
: PAL was supported by the SUCCESS-Program of the Philipps-University of Marburg and the ‘Stiftung zur Förderung junger Neurowissenschaftler’. MBo is a scientific consultant for Brainlab. HSD was funded by the EU Joint Programme – Neurodegenerative Disease Research (JPND), the Prof. Klaus Thiemann Foundation in the German Society of Neurology, the Felgenhauer Foundation, the KoelnFortune program of the Medical Faculty of the University of Cologne and has received honoraria by Everpharma, Kyowa Kirin, Bial, Oruen, and Stadapharm. SS reports no financial disclosures. SK reports no financial disclosures. CN is a scientific consultant for Brainlab. LT received payments as a consultant for Medtronic Inc. and Boston Scientific and received honoraria as a speaker on symposia sponsored by Bial, Zambon Pharma, UCB Schwarz Pharma, Desitin Pharma, Medtronic, Boston Scientific, and Abbott. The institution of LT, not LT personally, received funding by the German Research Foundation, the German Ministry of Education and Research, and Deutsche Parkinson Vereinigung. DJP has received honoraria for speaking at symposia sponsored by Boston Scientific Corp, Medtronic, AbbVie Inc, Zambon and Esteve Pharmaceuticals GmbH. He has received honoraria as a consultant for Boston Scientific Corp and Bayer, and he has received a grant from Boston Scientific Corp for a project entitled “Sensor-based optimisation of Deep Brain Stimulation settings in Parkinson’s disease” (COMPARE-DBS). The institution of DJP, not DJP personally, has received funding from the German Research Foundation, the German Ministry of Education and Research, the International Parkinson Foundation, the Horizon 2020 programme of the EU Commission and the Pohl Foundation in Marburg. Finally, DJP has received travel grants to attend congresses from Esteve Pharmaceuticals GmbH and Boston Scientific Corp. MBe reports no financial disclosures.
